New Two-Pronged attack on tough bladder cancer

NCT ID NCT06972615

Not yet recruiting Disease control Sponsor: BLATAM Source: ClinicalTrials.gov ↗

Summary

This study is testing a two-part treatment for people with high-risk bladder cancer that has not responded well to the standard BCG therapy. Participants will receive a chemotherapy wash directly into the bladder every 3 weeks, combined with an IV immunotherapy drug every 6 weeks, for one year. The main goals are to see if this combination can eliminate the cancer and to monitor its safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BLATAM

    CABA, 1123, Argentina

Conditions

Explore the condition pages connected to this study.